Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Summit Therapeutics (SMMT) FCF Margin (2022 - 2024)

Summit Therapeutics' FCF Margin history spans 2 years, with the latest figure at 1063.77% for Q2 2024.

  • For Q2 2024, FCF Margin changed N/A year-over-year to 1063.77%; the TTM value through Mar 2025 reached 5599.52%, up 259272.0%, while the annual FY2022 figure was 5986.67%, 195720.0% down from the prior year.
  • FCF Margin reached 1063.77% in Q2 2024 per SMMT's latest filing, up from 965.65% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1063.77% in Q2 2024 to a low of 3879.55% in Q3 2022.